Onesource Specialty Pharma Ltd.
1,583.40+14.4 (+0.92%)
8 Sep, 12:00 AM
Income Statement
Abridged
Understanding Income Statement
Onesource Specialty Pharma Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.
Balance Sheet
Abridged
Understanding Balance Sheet
Onesource Specialty Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.
Cash Flow
Abridged
Understanding Cash Flow Statement
Onesource Specialty Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.
Business Segment Analysis
FY End:
Mar 26
Onesource Specialty Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.
Capex
Contract Development and Manufacturing Organization (100.0%)₹ 569.07 Cr
Revenue / Sales
Contract Development and Manufacturing Organization (100.0%)₹ 1,421.59 Cr
Assets
Contract Development and Manufacturing Organization (100.0%)₹ 8,210.01 Cr
Operating Income
Contract Development and Manufacturing Organization (100.0%)₹ -6.11 Cr
Regional Segment Analysis
FY End:
Mar 26
Onesource Specialty Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.
Revenue / Sales
United States of America (USA) (34.7%)₹ 493.37 CrIndia (27.9%)₹ 396.29 CrRest of the world (21.7%)₹ 308.12 CrSpain (10.8%)₹ 153.85 CrIreland (4.9%)₹ 69.96 Cr
Historical Segment Analysis
Track how Onesource Specialty Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.
Business
Frequently Asked Questions
What is the revenue of Onesource Specialty Pharma Ltd.?
The latest trailing twelve month revenue of Onesource Specialty Pharma Ltd. is ₹ 1,543.34 Cr, reflecting a 1-year growth of 27.15% and a 3-year CAGR of 232.38%. Annual and quarterly revenue trends are available in the Income Statement section.
What is the net profit of Onesource Specialty Pharma Ltd.?
The latest trailing twelve month net profit (PAT) of Onesource Specialty Pharma Ltd. is ₹ -48.62 Cr, with a 3-year earnings CAGR of 43.82%. Detailed profit history across annual and quarterly periods is in the Income Statement section.
What is the EBITDA of Onesource Specialty Pharma Ltd.?
The trailing twelve month EBITDA of Onesource Specialty Pharma Ltd. is approximately ₹ 56.05 Cr (based on an operating margin of 3.63%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.
What is the EPS of Onesource Specialty Pharma Ltd.?
The trailing twelve month Earnings Per Share (EPS) of Onesource Specialty Pharma Ltd. is -4.24. EPS trends across annual and quarterly periods are visible in the Income Statement section.
What is the debt level of Onesource Specialty Pharma Ltd.?
The debt-to-equity ratio of Onesource Specialty Pharma Ltd. stands at 0.26. The interest coverage ratio is 0.45x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.
What is the book value per share of Onesource Specialty Pharma Ltd.?
The estimated book value per share of Onesource Specialty Pharma Ltd. is 508.52 (derived from a P/B ratio of 3.11 and market price of ₹ 1,583.40), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.
What is the cash flow from operations of Onesource Specialty Pharma Ltd.?
The trailing twelve month operating cash flow of Onesource Specialty Pharma Ltd. is ₹ -110.58 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.
Does Onesource Specialty Pharma Ltd. report consolidated or standalone financials?
Onesource Specialty Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.